GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Is Trending Stock Gilead Sciences, Inc. ( GILD ) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Company News for Aug 11, 2025
Companies In The News Are: GILD, TTD, TXRH, GEN.
Why Is Gilead Sciences Stock Surging Friday? - Gilead Sciences ( NASDAQ:GILD )
Q2 adjusted EPS of $2.01 beat the $1.94 consensus; revenue hit $7.08 billion vs. $6.94 billion estimate. Biktarvy sales rose 9% to $3.5 billion; Descovy surged 35% to $653 million amid higher demand and pricing. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session ...
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday - Blue Gold ( NASDAQ:BGL ) , Astrana Health ( NASDAQ:ASTH )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Friday. Shares of SoundHound AI, Inc. SOUN rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates.
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Gilead Sciences ( GILD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc. ( "Assembly Bio" ) ( Nasdaq: ASMB ) , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering ( the ...
Gilead Sciences ( GILD ) Tops Q2 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings - Gilead Sciences ( NASDAQ:GILD )
A more conservative goal of $100 monthly dividend income would require 380 shares of Gilead Sciences. An investor would need to own $209,422 worth of Gilead Sciences to generate a monthly dividend income of $500. The market's back, and these 3 income stocks are thriving. See them here→
Jobless Claims Increased More Than Expected
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Jobless Claims, Q2 Productivity, Q2 Earnings All Higher
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Arcus ( RCUS ) Q2 Revenue Jumps 310%
Arcus Biosciences ( NYSE:RCUS ) , a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both surpassed Wall Street expectations by a wide margin, with reported GAAP revenue at $160 million ...
Aisera Launches Unify - The AI Industry's First Open Architecture for Multi-Agent Orchestration
SANTA CLARA, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Aisera, a leading provider of agentic AI for enterprise, today announced the launch of Aisera Unify, the industry's first open standards-based communication backbone and underlying architecture that enables multi-agent orchestration across ...
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Seeking Clues to Gilead ( GILD ) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Vor Biopharma ( NASDAQ:VOR )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio VOR, a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities ...
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
BEIJING, China, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Pheton Holdings Ltd ( the "Company," "we," "our" or "Pheton" ) , a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in ...
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - Ligand Pharmaceuticals ( NASDAQ:LGND ) , Medtronic ( NYSE:MDT )
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement
Gilead Sciences ( GILD ) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Gilead Sciences, Inc. ( GILD ) Worth Betting on Now?
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences ( GILD ) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.
Why Gilead Sciences Stock Slipped Today
Changes in a federal healthcare authority could negatively impact one of the company's important businesses.
Visa, Disney, Blackstone And A Health Care Stock On CNBC's 'Final Trades' - Blackstone ( NYSE:BX ) , Walt Disney ( NYSE:DIS )
On CNBC's "Halftime Report Final Trades," Stephanie Link, Chief Investment Strategist at Hightower Advisors, picked Visa Inc. V as her final trade. Visa will report its fiscal third quarter financial results on Tuesday, July 29. Analysts expect the company to report quarterly earnings at $2.85 ...
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
- Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates ...
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
- Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates - - Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted -
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop - Assembly Biosciences ( NASDAQ:ASMB )
- Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates - - Preclinical data and U.S. genital herpes prevalence and treatment patterns also highlighted -
Why Gilead Sciences Stock Just Popped
Gilead stock is flashing "buy" in bright green letters.
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Gilead Sciences ( NASDAQ:GILD )
Needham upgrades Gilead to Buy with $133 target on Yeztugo's strong physician support Yeztugo could generate $6.4 billion by 2035, 20% above consensus expectations Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On In June, the U.S.
Price Over Earnings Overview: Gilead Sciences - Gilead Sciences ( NASDAQ:GILD )
In the current session, the stock is trading at $114.58, after a 1.22% spike. Over the past month, Gilead Sciences Inc. GILD stock increased by 4.54%, and in the past year, by 48.84%.
Here's Why Gilead Sciences ( GILD ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Applied Digital ( NASDAQ:APLD ) , Carvana ( NYSE:CVNA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Joseph Stringer upgraded the rating for Gilead Sciences, Inc.
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., July 24, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. The company will hold a conference call beginning at 8:30 a.m.
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
Ligand to Report Second Quarter 2025 Financial Results on August ...
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock ( NASDAQ:SRRK ) in an open market transaction.Source: SEC Form 4 filing from July 18. The insider transaction occurred on July 16.How does the transaction compare to previous insider activity?This is ...
Gilead Sciences ( GILD ) Beats Stock Market Upswing: What Investors Need to Know
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
NEW YORK and VIENNA, July 18, 2025 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, "HOOKIPA" ) , a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to ...
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Aisera announces availability of Aisera Assistant in the new AWS Marketplace for AI Agents and Tools category
SANTA CLARA, Calif., July 17, 2025 ( GLOBE NEWSWIRE ) -- Aisera, a leading provider of agentic AI for business, today announced the availability of Aisera Assistant in the new AI Agents and Tools category of AWS Marketplace.
